J Liver Cancer Search

CLOSE


Journal of the Korean Liver Cancer Study Group 2012;12(2):128-132.
Published online September 30, 2012.
A Case of Combination Therapy Using Radioembolization and Transarterial Chemoembolization with Drug-eluting Beads in Bilobar Hepatocellular Carcinomas
Hee Yeon Kim1, Chung-Hwa Park1, Do Seon Song1, Myeong Jun Song1, Jong Young Choi1, Seung Kew Yoon1, Si Hyun Bae1, Ho Jung Chun2
1Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Department of Interventional Radiology, College of Medicine, The Catholic University of Korea, Seoul, Korea
Correspondence:  Si Hyun Bae,
Email: baesh@catholic.ac.kr
Abstract
Bilobar multifocal hepatocellular carcinomas (HCCs) can be treated with transarterial radioembolization in a sequential lobar, or whole liver manner. However, radioembolization could result in a risk of radiation-induced liver toxicity in patients with reduced functional reserve. Here we describe a case with bilobar HCCs successfully treated with a combination therapy using radioembolization and transarterial chemoembolization with drug-eluting beads without significant side effects. A 72-year-old female with liver cirrhosis was diagnosed of hepatocellular carcinoma with bilobar involvement. The main mass in the left lobe was treated with radioembolization while the other lesion in the right lobe was treated with transarterial chemoembolization using drug-eluting beads, and the patient was tolerable. A combination of radioembolization and selective transarterial chemoem- bolization may be considered for an alternative option in patients with bilobar multifocal HCCs with decreased liver function.
Key Words: Hepatocellular carcinoma; Bilobar; Radioembolization; Drug-eluting bead
NULL


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR AUTHORS AND REVIEWERS
Editorial Office
1521 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2022 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next